![]() |
New to the Huntington's
Disease Lighthouse? |
||
| |
| |
| |
| |
| |
| |
| |
||
Research Study for Those At RiskJessica Young You are invited to participate in a study conducted by researchers at the Johns Hopkins University and the National Human Genome Research Institute. The purpose of our study is to learn more about how people who are at risk for Huntington’s disease are talking about Huntington’s disease to family and close friends and to learn how people are adapting to their risk for Huntington’s disease. By understanding more about this process, we hope that healthcare providers will be able to better serve their patients who are at risk for Huntington’s disease. The study involves filling out one survey that takes about 30-40 minutes to complete. If you take part in the study, you will be reimbursed with a $5 gift card to Wal-Mart for your time. The survey asks about your communication about Huntington’s disease to family and close friends and also asks about your general thoughts and feelings about yourself and your life. In order to take part in the study, you must fulfill the following eligibility criteria:
There are two ways to take the survey:
If you decide to fill out the paper copy, you will find two versions of the survey. You only need to complete only the survey version that applies to you. Survey A is for people who have had genetic testing for Huntington’s disease. Survey B is for people who have not had genetic testing for Huntington’s disease, but are at risk for Huntington’s disease based on a family history of Huntington’s disease. Please complete only the survey version that applies to you. If you are willing to take part in this study, please read the consent form (within the survey) and check the box that acknowledges that you have read and agreed to the terms presented in the consent document. In addition, if you are willing, please feel free to pass on the online survey link and the password to others who might be eligible (see criteria above) and willing to fill out the survey. If the person would prefer to fill out a paper version of the survey, please ask them to contact the researchers (contact information below). If you have any problems or questions about this study, or about your rights as a participant, please contact the researchers (contact information below). Thank you for your time and for being willing to fill out this survey. We look forward to learning from your answers. Sincerely, Jessica Young, BS Barbara Biesecker, MS, CGC Social and Behavioral Research Branch Source: JHU/NHGRI Genetic Counseling Program
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Research related HD and it's general affect on the brain
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
24 May 2010
Neurosearch Amends the ACR-16 Results
Statistical significance not achieved on primary endpoint. 3 Feb 2010
The European trial of ACR16 yields good results
ACR16 improves voluntary and involuntary movement. This is wonderful news! 31 Jan 2010
A Sirtuin Inhibitor Enters Phase1a Clinical Trials in Europe
Siena Biotech announces a safety and tolerability study with healthy volunteers, preparatory to trials in HD patients. 3 Jun 2009
Medivation to begin a Phase III trial of Dimebon
Medivation is sponsoring a randomized, double-Blind, placebo-controlled, Phase III trial of Dimebon in patients with mild to moderate Huntington’s Disease 23 Apr 2009
Minocycline Phase II clinical trial results are disappointing
18 Jul 2008
Participants needed for qualitative studies of JHD
The University of Iowa is recruiting participants for two important new studies. 9 Jun 2008
The Research Pipeline - taking drugs from the lab to the clinic
Here\'s an overview of some of the more promising potential treatments moving through the research pipeline. 12 Mar 2008
Phase III creatine trial
NCCAM and the Orphan Product Division of the FDA is funding a phase III clinical trial of medicinal grade creatine. 1 Oct 2007
ACR16 closer to Phase III clinical trials
Neurosearch applies for permission to start Phase III clinical trials of ACR16, a dopamine stabilizer, in Europe and the U.S. 30 Sep 2007
Research Study for those At Risk
Last call for participants in an At Risk study. All Updates for Clinical Trials |
|||||||||||||||||
| Disclaimer &
Privacy Policy | |
|